Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AchALS: PEA in ALS
NCT02645461Completed
- Sponsor
- Sapienza University of Rome
- Start
- Jan 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of palmitoylethanolamide in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Sapienza University of Rome. Primary endpoint: Forced Vital Capacity at 6 months. Started Jan 2014; status: completed.
02
Drugs
palmitoylethanolamide
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02645461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02645461.